Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

Compounded GLP-1 drugs. Perhaps you’ve heard about them?

Unfortunately, many are hearing a drugmaker-spun narrative about GLP-1 compounding that simply isn’t accurate, and in some cases, it’s downright nonsense. 

To help confront the issue — and set the record straight — we feature at the top of our homepage at a4pc.org a box containing links to accurate explanations about compounding and GLP-1s. It’s useful info not only for reporters, but for you, your team, and even (especially!) prescribers you work with. Give ’em a look, get briefed, and share. It’s the only way the truth about compounding will prevail.